SelectMDx
Prostate Cancer (Initial risk assessment for biopsy decision)
CommercialMarketed
Key Facts
Indication
Prostate Cancer (Initial risk assessment for biopsy decision)
Phase
Commercial
Status
Marketed
Company
About MDxHealth
MDxHealth is a Nasdaq-listed precision diagnostics company dedicated to personalizing urologic care, primarily in prostate cancer. Its strategy centers on commercializing and expanding a menu of proprietary, non-invasive and tissue-based molecular tests, such as ConfirmMDx, GPS, SelectMDx, and ExoDx, which are supported by extensive clinical validation. The company aims to grow by increasing test adoption, securing favorable payer reimbursement, and leveraging its commercial infrastructure to enhance patient access and clinical utility.
View full company profile